Key takeaways:
A prior authorization request is the most common rejection you’ll see, and it’s a clinical case, not a form. What resolves it is providing a documented reason for why the plan’s preferred medication(s) won’t work.
“Refill too soon” and out-of-network rejections can usually be resolved at the pharmacy or by routing the prescription correctly. They rarely need a clinical decision from you.
A drug utilization review (DUR) rejection is the one type you’re going to handle yourself. It’s a safety flag built from the plan’s claims data, so don’t let someone override it without your input.
Insurance is one of the parts of clinical practice no one really trains you for, and early on it can feel like a black box. You write a prescription, and a day or two later it comes back: the pharmacy wants $400, or a prior authorization, or the plan won’t cover it at all.
Everything that happened in between was invisible to you. It wasn’t random, though, and it wasn’t the pharmacist’s decision — it was the patient’s plan applying predetermined rules. The good news is that a fair number of those rules turn out to be things you can control.
Here we’ll take a look at four common reasons for rejections, and what you can do if they happen.
1. Prior authorization
Prior authorizations (PAs) are one of the most common kinds of rejections. A PA helps payers control cost by increasing use of medications on their preferred formulary.
The fastest way to handle PAs is to use an electronic PA (e-PA) service. The e-PA process looks like this:
The prescription is sent to the pharmacy, and the pharmacy receives a PA rejection from the insurance company.
The pharmacy sends a PA request to the provider’s office. This request already includes most of the patient’s basic information, including the medication being requested.
The office staff logs into the e-PA account and completes the request, which includes answering clinical questions and sometimes attaching chart notes.
Insurance companies sometimes deny prior authorizations. They often will not approve a non-formulary product unless:
A person has already tried their plan’s preferred products
A person has an intolerance or contraindication to the preferred products
A prescriber demonstrates that switching medications is essential to treatment success
What to do
Most of the time, a prior authorization isn’t the end of the road. There are a few steps you can take.
Give a real clinical reason. This is the single most useful thing to know. A formulary exception isn’t a form to fill out, it’s a clinical case. The plan is asking why its preferred alternatives won’t work for this patient. “The patient prefers it” or “I’ve had good results with it” won’t clear the bar. A documented failed trial, intolerance, contraindication, or drug interaction will. The clearer and more specific your reason, the faster the process moves.
Ask for speed when it matters. You can request the coverage determination yourself, on the patient’s behalf. And if a delay could seriously jeopardize the patient’s health, you can ask the plan to expedite it. On Medicare, that shortens the decision from 72 hours to 24.
Remember that a physician order may not be necessary. The rules say “physician or other prescriber,” which covers anyone licensed under state law (like an NP or PA) to write the prescription. If that’s you, you can request the determination, ask for expedited review, and file the appeal — no attending co-signature required.
If it’s denied, you can appeal. A denial can be escalated — first back to the plan, then to an independent reviewer, and further if it comes to that. When a peer-to-peer review is offered — a quick call with the plan’s physician — it’s often the fastest way to turn a no into a yes, and usually beats a written appeal. When the rejection is due to step therapy requirements, the fastest path is usually documenting what the patient already tried rather than arguing the policy.
2. Refill too soon
“Refill too soon” rejections happen because a person is trying to get their medication before the payer thinks it’s due. In some cases, the pharmacist can obtain a “refill too soon override” for these rejections.
Vacation override: If the person is going on vacation and would run out of medication before getting back, they may be able to get a refill early. But this is often limited to one or two overrides per year.
Medication synchronization: Medication synchronization is an adherence service where the pharmacy aligns a person’s refills to be filled on the same day each month. The pharmacy has to fill a small quantity of medication to align them. Some insurers will pay for medication synchronization. But it’s possible for these small fills to initially trigger a “refill too soon” rejection.
3. Drug utilization review
Drug utilization review (DUR) rejections are a quality assurance measure that are different from the other rejections. They’re clinical alerts built from the plan’s claims history, so this category of rejection should not be delegated. Examples include:
Medication interaction
Medication-disease contraindication
Dosing error
Clinical precaution
When a DUR shows up, a pharmacist can often clear it with an override code, but some codes require the pharmacist to attest that they spoke with you first. That’s why a DUR rejection usually reaches your office as a phone call rather than a delegated task.
It’s important to handle the issue yourself. The plan has flagged a real safety question, and the answer is a clinical decision, not a clerical one: confirm the order is intentional and appropriate, or review the flag and change your prescription. It’s the one rejection where pushing it through without a look is the wrong reflex.
4. Out-of-network
Insurance plans often steer specialty and high-cost drugs to one or two in-network mail-order or specialty pharmacies. When a claim is rejected for this reason, the drug is usually covered — just not at the pharmacy you prescribed it to.
To solve this, simply route the prescription to an in-network pharmacy. The receiving pharmacy can sometimes transfer it, but that’s slower, especially when it means reaching a mail-order pharmacy. So sending a fresh prescription to the right place is often the faster path.
Also, keep in mind that a patient’s network can change at the start of the plan year or after a job change. So just because you sent the same prescription for the same medication for the same patient last month without an issue doesn’t mean you can’t get an out-of-network message this month.
Prescribing tips
A surprising number of rejections start with the prescription, not the plan:
Quantity and days’ supply that don’t match the package. Inhalers, eye drops, insulin pens, and topicals are the usual offenders. A quantity of “1” on something dispensed in grams or milliliters will get rejected.
A missing indication on a Medicare B/D drug, which turns an easy fill into a prior authorization.
Brand intent that isn’t documented. If you want the brand dispensed, it has to be unambiguous on the prescription.
It also helps to know the price before the patient leaves. Consider using real-time benefit tools in the EHR and cost-comparison tools like GoodRx for healthcare professionals. They can show you what a drug costs on that patient’s plan and what it costs in cash, while you can still change course.
The bottom line
Most pharmacy rejections aren’t random, and most aren’t the pharmacist’s responsibility to fix — they’re the patient’s plan applying rules you can usually work with. The message tells you which rule got flagged, and that tells you who resolves it and what it takes. Sometimes you’ll need a documented clinical reason for a prior authorization, other times a corrected quantity or the right pharmacy is the right fix. And a DUR flag will need your own set of eyes. Sorting the rejection quickly is what saves you and your staff time and gets your patient their medication sooner.
Why trust our experts?
References
American Medical Association. (2017). Reduce practice burdens with electronic prior authorization.
American Medical Association. (2023). Prior authorization practice resources.
AMCP. (n.a.). Drug utilization review.
Code of Federal Regulations. (2026). 42 CFR Part 423 Subpart M: Grievances, coverage determinations, redeterminations, and reconsiderations.
